十氢萘-1-酚 | 529-32-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 十氢萘-1-酚
• 英文名称: 1-decalinol
• 英文别名: decahydronaphthalen-1-ol；hydroxy-dihydronaphthalene；Decahydro-1-naphthol；1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-ol
• CAS: 529-32-8
• 化学式: C₁₀H₁₈O
• mdl: MFCD00070718
• 分子量: 154.252
• InChiKey: NDZOISQLWLWLEW-UHFFFAOYSA-N

物化性质

• 熔点：
  48-50℃
• 沸点：
  238℃
• 密度：
  0.992
• 闪点：
  102℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2907199090

SDS

Name:	Cis-Decahydro-1-Naphthol Material Safety Data Sheet
Synonym:	None
CAS:	529-32-8

Section 1 - Chemical Product MSDS Name:Cis-Decahydro-1-Naphthol Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
529-32-8	Cis-Decahydro-1-Naphthol	ca 100	208-458-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 529-32-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 238 deg C @ 760.00mmHg
Freezing/Melting Point: 89.00 - 92.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H18O
Molecular Weight: 154.25

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 529-32-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Cis-Decahydro-1-Naphthol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 529-32-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 529-32-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 529-32-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  十氢萘-1-酚 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 potassium tert-butylate 、 溴 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  使用1°和2°醇进行氢借入催化：导致α和β支链产物的研究和范围

  摘要：

  描述了在氢借位催化下使用1°或2°醇对各种酮进行的烷基化。最初的研究集中在环丙酮与更高的1°醇（即大于MeOH）的α-烷基化反应上，导致形成α-支化产物。我们通过寻找其他底物来探索这种化学反应，使我们发现，二邻位取代的芳基酮也是特有的支架，其中Ph ∗（C 6 Me 5）酮是最佳选择。进一步的研究表明，该基序对于与2°醇形成β支链产物的烷基化至关重要，这也为研究非对映选择性和分子内氢借入过程提供了机会。

  DOI：

  10.1016/j.tet.2021.132051
• 作为产物：
  描述：

  3,4-二氢-1(2H)-萘酮 在 Rh/Al₂O₃ 氢气 作用下， 以 乙醇 为溶剂， 以95%的产率得到十氢萘-1-酚
  参考文献：
  名称：

  Mechanism of the transannular cyclization of 5-cyclodecynone

  摘要：

  DOI：

  10.1021/jo00274a018

文献信息

• Central nervous system antiischemic agents
  申请人：Bristol-Myers Squibb Company

  公开号：EP0559569A1

  公开（公告）日：1993-09-08

  A series of phenylalkylaminoalkyl derivatives of Formula I wherein Ar is naphtyl or phenyl;    R¹ is hydrogen, fluoro or R⁴CONH-;    R² is hydrogen or C₁-₆ alkyl;    R₃ is C₁-₆ alkyl;    R⁴ is C₁-₆ alkyl or phenyl- C₁-₆ alkyl;    x is zero or the integers 1 and 2;    m is selected from the integers 1 to 6; and    n is selected from the integers 2 and 3, has been found to provide effective antiischemic protection for CNS tissue, particularly neurons. A method of treatment to protect against CNS ischemia, such as that resulting from trauma or stroke or other ischemic conditions, comprises administration of these novel compounds to an individual in need of such treatment.

  一系列的Formula I的苯基烷基氨基烷基衍生物已被发现能够为中枢神经系统组织，特别是神经元，提供有效的抗缺血保护。一种治疗方法用于保护中枢神经系统缺血，例如由创伤、中风或其他缺血病症引起的缺血情况，包括将这些新化合物用于需要此类治疗的个体。其中Ar为萘基或苯基；R¹为氢、氟或R⁴CONH-；R²为氢或C₁-₆烷基；R₃为C₁-₆烷基；R⁴为C₁-₆烷基或苯基-C₁-₆烷基；x为零或整数1和2；m从整数1到6中选择；n从整数2和3中选择。
• Selective activation of secondary C–H bonds by an iron catalyst: insights into possibilities created by the use of a carboxyl-containing bipyridine ligand
  作者：Shi Cheng、Jing Li、Xiaoxiao Yu、Chuncheng Chen、Hongwei Ji、Wanhong Ma、Jincai Zhao

  DOI：10.1039/c3nj00656e

  日期：——

  4′-dicarboxylic acid), which could activate the C–H bonds of cycloalkanes with high secondary (2°) C–H bond selectivity. A turnover number (TN) of 11.8 and a 30% yield (based on the H2O2 oxidant) were achieved during the catalytic oxidation of cyclohexane by 1 under irradiation with visible light. For the transformation of cycloalkanes and bicyclic decalins with both 2° and tertiary (3°) C–H bonds, 1 always preferred

  在这项工作中，我们报告发现了一种含羧基的铁催化剂1（Fe II -DCBPY，DCBPY = 2,2'-联吡啶-4,4'-二羧酸），该催化剂可以活化环烷烃的C–H键具有较高的次级（2°）CH键选择性。在H2O2的催化氧化过程中达到了11.8的周转数（TN）和30％的收率（基于H 2 O 2氧化剂）。环己烷在可见光照射下，按1。对于具有2°和叔（3°）C–H键的环烷烃和双环十氢化萘的转化，1总是优选将2°C–H键氧化为相应的酮和醇产物；在7个示例中，2°/ 3°的比率介于78/22和> 99/1之间。用18 O同位素标记实验，ESR实验，PPh 3方法和过氧化氢酶方法表征了氧化过程中的反应过程。1的成功表明，除了使用体积较大的催化剂外，使用体积较小的分子铁络合物作为催化剂也可以实现较高的2°C–H键选择性。
• [EN] 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS<br/>[FR] ANALOGUES DE PYRIDAZINE 1,4-DISUBSTITUÉE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS À UNE DÉFICIENCE EN SMN
  申请人：NOVARTIS AG

  公开号：WO2014028459A1

  公开（公告）日：2014-02-20

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物或其药用可接受的盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS
  申请人：AXFORD Jake

  公开号：US20140206661A1

  公开（公告）日：2014-07-24

  The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式（X）的化合物或其药用盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014078813A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

  本发明提供了式I的化合物：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物治疗、预防、抑制、改善或根除由疟原虫引起的疟疾等疾病的方法。